Compliance Navigator Blog

Healthcare technology is increasingly digital, connected and data-driven. Medical device and IVD manufacturers are therefore influenced not only by sector-specific standards, but also by a wider set of “adjacent” standards that address cybersecurity, information management, data governance, sustainability and interoperability. These standards are not written specifically for healthcare, but they play an important role in how healthcare technologies are designed, deployed and maintained.

Most medical device and in vitro diagnostic device manufacturers already rely on established international standards. Quality management, risk management, software lifecycle and clinical investigation standards are often embedded in organizational processes long before EU regulations apply. Harmonisation under EU law is therefore primarily about whether existing standards can formally support regulatory compliance, rather than creating new documents. This article explains how that process works, what changes when a standard is harmonised, and how manufacturers deal with limitations in coverage.

On 16 June 2025, new post-market surveillance (PMS) requirements came into force in Great Britain under The Medical Devices (Post-market Surveillance Requirements) (Amendment) Regulations 2024 (SI 2024 No. 1368). These changes apply to manufacturers placing medical devices and in vitro diagnostic (IVD) devices on the market in England, Wales and Scotland.

ISO 15223-1 is a crucial standard for medical device manufacturers, providing symbols to convey information about devices without relying on text. This minimizes translation needs, frees up label space, and meets various regulatory requirements. On March 5, 2025, ISO 15223-1:2021/Amd 1:2025 introduced a significant change to the Authorized Representative symbol, altering the [EC] part of the symbol to [XX]. This change allows the symbol to be used globally, not just within the European Union, by replacing [XX] with country codes or other recognized text.

The MedTech and healthcare sectors have long been seen as leaders in innovation, consistently pushing the boundaries of what is possible in diagnosing, preventing, monitoring, and treating diseases. These advancements are also bringing an increased awareness of the impact current healthcare practices and legacy devices are having on the environment. Changing the way we deliver healthcare and design healthcare products is essential for minimising the environmental impact and creating a sustainable future for the MedTech and healthcare industries.

This is the latest blog in the Creating a Circular Eco-System for Medical Device series that aims to highlight different aspects and challenges of a circular economy in the healthcare and medical device industries. It addresses the principle of reuse and the struggle with choosing single-use or reusable devices, focusing on four (of many) areas that a manufacturer must consider.

Sustainability focuses on the overarching principles for addressing three main pillars: environment, economy, and society. It is industry agnostic and culturally neutral, meaning that it applies to everyone, everywhere. This is the first in a series of blogs highlighting different aspects of these pillars as they pertain to and impact on the healthcare and medical device industries.

The final rule incorporates by reference (IBR) ISO 13485:2016 into the FDA regulation, expanding on a few provisions to ensure consistency with other applicable FDA regulations, including definitions and requirements. The new requirements become effective 2 February 2026. The structure of the QMSR will change to support the IBR of ISO 13485:2016 and remove those subparts that the FDA has determined to be substantively similar. There are only four areas where the requirements of ISO 13485:2016 and QMSR (new Part 820) are not substantively similar. There is, however, another part of the Final Rule that plays a critical role in the application of the QMSR and provides additional supportive information. That part is called the Preamble.

It has now been two months since the US Food and Drug Administration (FDA) published its final rule amending the Current Good Manufacturing Practice (CGMP) requirement of the Quality System Regulation (QSR) (21 CFR Part 820) to incorporate by reference, and thereby align more closely with, the international consensus standard ISO 13485:2016, Medical devices—Quality management systems—Requirements for regulatory purposes.  The new regulation, referred to as the Quality Management System Regulation, or QMSR for short, is the medical device industry’s latest significant regulatory change and move towards more consistency in the global regulatory framework. With the publication of the final rule, the FDA have provided additional clarification and information so manufacturers may start to plan implementation strategies ahead of the effective date of 2 February 2026.

Over the past years, the US FDA has announced a number of initiatives, including Ethylene Oxide (EO) Innovation Challenges and Master File Pilot programs, to advance innovation and streamline the regulatory pre-market approval process. On 8 January 2024, the US FDA announced the re-issue of the guidance titled “Submission and Review of Sterility Information in Premarket Notification (510(k)) Submissions for Devices Labeled as Sterile”, superseding its 2016 version. In this blog, we will explore what are the significant changes in the guidance; what prompted these changes; and what are the implications for medical device manufacturing.

After years of speculation by the medical device community, on 2 February 2024, the US Food and Drug Administration (FDA) published its final rule amending the current good manufacturing practice (CGMP) requirement of the Quality System Regulation (QSR) to incorporate by reference, and thereby align more closely with, the international consensus standard ISO 13485:2016, Medical devices—Quality management systems—Requirements for regulatory purposes. The new regulation is called the Quality Management System Regulation (QMSR) Final Rule and is the latest significant regulatory change affecting the global medical device industry.

The medical device industry is immersed in innovation, consistently pushing the boundaries of what is possible in healthcare. Amidst these advancements, two essential concepts have emerged that are seen as both enablers and inhibitors to innovation: Sustainability and the circular economy. While often used interchangeably, they represent distinct approaches to addressing environmental, economic, and global supply chain challenges. In this blog, we will explore the key differences between sustainability and the circular economy in the medical device industry.

The regulation of medical devices and in vitro diagnostic (IVDs) medical devices in Northern Ireland is governed by the Windsor Framework. This means that the EU Medical Device Regulation ((MDR)(EU) 2017/745 and In Vitro Diagnostic Medical Device Regulation (IVDR) (EU) 2017/746 have applied in Northern Ireland in line with the respective dates of application across the EU. The Medicines and Healthcare Products Regulatory Authority (MHRA) is the de facto Competent Authority for Northern Ireland and has specific requirements for registration, vigilance reporting etc.

Achieving EN 60601 compliance involves several steps to ensure that your medical electrical equipment meets the safety and essential performance requirements specified by the standards. Below are the main steps towards compliance:

Several schemes operate for EN 60601 to facilitate compliance, certification, and market access for medical electrical equipment. Below we provide an overview of a few key ones.

EN 60601 specifies a set of requirements that medical electrical equipment and systems must meet to ensure safety and essential performance. The specific requirements vary depending on the part and edition of the standard. Below you can find an overview of the general categories of requirements covered by EN 60601:

IEC 60601 refers to a series of international standards that pertain to the basic safety and essential performance of medical electrical equipment. These standards are issued by the International Electrotechnical Commission (IEC), a global organization that develops and publishes international standards for electrical, electronic, and related technologies and has been adopted by CENELEC without technical modification for use in Europe where it is designated EN 60601.

It has been more than 6 years now that ISO 9001 has been using the High-Level Structure (HLS) as outlined in the ISO/IEC Directive, Part 1. There have not been any significant problems created by the divergence of the two standards. In this update we will discuss the current activities by both Technical Committees and other activities by the ISO organization and others that could be of significance. While there are still many people that focus on the differences, it is clear that the standards continue to be used alongside each other without significant issues as there remains no direct conflict between the requirements. In part 2 of the series, we're focussing on the similarities between the two standards and summarising our main points.

It has been more than 6 years now that ISO 9001 has been using the High-Level Structure (HLS) as outlined in the ISO/IEC Directive, Part 1. There have not been any significant problems created by the divergence of the two standards. In this update we will discuss the current activities by both Technical Committees and other activities by the ISO organization and others that could be of significance. While there are still many people that focus on the differences, it is clear that the standards continue to be used alongside each other without significant issues as there remains no direct conflict between the requirements.

On 7th March 2023, the Medicines and Healthcare products Regulatory Agency (MHRA) advisory group proposed a significant regulatory reform. [1] Its proposal is to build "… on current product recognition routes from the EU, [and to] rapidly explore building a UK product regulation equivalence route for the approvals of medical devices to include other trusted jurisdictions such as the US for a greater proportion of products." What does recognition mean for UK patients and for the HealthTech industry in the UK?

The Medicines and Medical Devices Act 2021 [1] gave legal power to the Medicines and Healthcare products Regulatory Agency (MHRA) to set up a new United Kingdom (UK) regulatory framework for medical devices and in vitro diagnostic devices (IVDs). This new primary legislation paved the way for the MHRA to update the existing secondary legislation - the UK Medical Devices Regulations 2002 [2]. According to the 2021 Act, new regulations must safeguard public health and, at the same time, have regard to the safety and availability of devices. The Act also means that new regulations must also make the UK a favourable place to research, develop, manufacture and supply medical devices. It is a requirement that the MHRA must carry out a public consultation before updating these and any future regulations.

The Medical Device Regulation (MDR) and the In Vitro Diagnostic Regulation (IVDR) reference several other directives and regulations. One such directive is the Product Liability Directive (PLD). Published in 1985, the PLD is a well-established mechanism for ensuring that manufacturers shall be liable for damage caused by a defect in their product. There are two important updates currently under consideration within the EU that could impact medical device manufacturers and patients alike.

The application of the AIA is expected to have a global effect as it has a horizontal applicability across industries, it covers all providers and users where the output of the AI system is used in the EU, and standardization creates harmonization increasing business opportunities for large markets such as the EU.

The EU legal framework was built around the notion that AI should be Ethical and Trustworthy. It is not therefore a surprise that AI practices that contradict basic human rights are considered prohibited. AIA (Council, Nov 2022)(Article 5) prohibits AI practices that might lead to physical or phycological harm (Fig. 1).

The definition of AI is important as it will dictate the products that fall under the scope of AIA, as well as filtering out products using the term AI incorrectly. A global concern on the definition of AI has been raised, leading to a broad range of definitions in official documents. Some of which are presented in Table 1 - Definitions (TC260, 2021) that make use of the term “intelligence”. These are ambiguous however, as there is no globally accepted definition of intelligence (Shane Legg, 2007) (Wang, 2019).

The transition period for the IVDR has now begun. The initial timeline for date of application, on 26 May 2022 (after which, no new IVDD certificates can be issued), has been partially extended to allow manufacturers to continue to sell “legacy” devices already placed on the EU market for up to an additional 5 years, depending on the risk class, as long as no significant changes are made to the device design or intended purpose. Any new devices placed on the market will need to conform to the revised rules of the IVDR.

Changes introduced in the instructions for MDSAP audits The Medical Device Single Audit Program (MDSAP) was developed to conduct regulatory audits of quality management systems (QMS) of manufacturers of medical devices. The MDSAP allows a single audit conducted by a recognized Auditing Organization (AO) to cover the requirements of BS EN ISO 13485:2016, together with specific regulatory requirements for the participating jurisdictions – Australia, Canada, Japan, Brazil and USA. Participation in the programme should reduce the need for duplicate audits and reduce the resource requirements on Regulatory Authorities and medical device manufacturers. Audits conducted in the MDSAP follow a prescribed process of defined tasks that the auditors have to perform. The audit tasks that have to be covered and the links to the applicable regulatory requirements for participating jurisdictions are identified in the MDSAP Audit Approach (MDSAP AU P0002). The 2023 update, issued in March, takes the document to revision 008.

Extension to EU Directives certificates will also apply in Great Britain and Northern Ireland To maintain patients’ access to a wide range of medical devices while ensuring the transition to the new regulations, the European Union has taken action to extend the validity of certificates issued under the Medical Devices (Directive 93/42/EEC) and Active Implantable Medical Devices Directives (Directive 90/385/EEC). The changes have been implemented by Regulation (EU) 2023/607 of the European Parliament and of the Council of 15 March 2023 amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards the transitional provisions for certain medical devices and in vitro diagnostic medical devices.

The requirements of the Regulation will inevitably lead to changes in your procedures for design and development. Design and development plans will need to be adjusted to:

The regulations define additional detail for the content of the Technical Documentation – often referred to as the Technical File – for each medical device or family and require that the information is presented in a clear, organized, readily searchable and unequivocal way. The regulations also reinforce the emphasis on the requirements driving a lifecycle approach to the management of the medical device with the routine updating of the Technical Documentation, including:

The Technical Committee responsible for standards on sterilization and washer disinfectors, ISO TC 198 – Sterilization of health care products – has a portfolio of standards that cover validation and routine control of sterilization processes, general requirements for sterilizers and standards for washer disinfectors. On January 2021, the committee published its first standard for sterilizing equipment; ISO TS SO/TS 22421:2021 - Sterilization of health care products — Common requirements for sterilizers for terminal sterilization of medical devices in health care facilities.

The European Commission’s Medical Device Coordination Group (MDCG) survey on notified body certification and application activities under the Medical Devices Regulation (EU 2017/745) (MDR) and In Vitro Medical Devices Regulation (EU 2017/746) (IVDR) showed the problems in the transition to the MDR and IVDR. A significant number of certificates for legacy medical devices expire on 26 May 2024.

European Commission set to add to list of Harmonised Standards in the Official Journal Harmonized European Standards have an important, specific role in supporting the European Regulations for medical devices (MDR) and in vitro diagnostic medical devices (IVDR). Article 8 of each Regulation indicates, that Harmonized Standards referenced in the Official Journal (OJ) of the European Union, provide a presumption of conformity with relevant requirements of the Regulation covered by those standards or applicable parts of standards. The presumption of conformity also applies to system or process requirements, including those requirements relating to quality management systems and risk management.

The IVDR shares many of its new features with the MDR (EU regulation 2017/745). Apart from the new elements shared with the MDR and the consequences for the market entry and surveillance (like the new supply chain regime, use of unique device identifiers (UDI) and a central database that is the European database on medical devices (EUDAMED)), there are three major reforms in the IVD field:

European Commission propose action as survey indicates that large majority of MDR certificates expire in 2024 The European Commission’s Medical Device Coordination Group (MDCG), has undertaken a survey to collect data on notified body certification and application activities under the Medical Devices Regulation (EU 2017/745) (MDR) and In Vitro Medical Devices Regulation (EU 2017/746) (IVDR).

The risk management process described in BS EN ISO 14971 [1] consists of several steps, as illustrated in Figure 1, which apply to the design, development, production and post-production stages of every medical device. The distinct process steps are numbered from 1 to 6 and discussed in detail in this paper.

BS EN ISO 14971 [1] provides a generic process for risk management of all kinds of medical devices, applicable to the entire life cycle from design and development through production and postproduction until decommissioning and disposal.

Following the end of the Brexit transition period, the EU Medical Devices Regulation (MDR), EU 2017/745, and In Vitro Diagnostic Medical Devices Regulation (IVDR), EU 2017/746, were not transposed into law in Great Britain.

Although the concept and requirements of performance evaluation have not really changed over 20 years, the required technical documentation has changed radically both in terms of content and amount required in the IVDR compared to the IVDD. The contents of two new IVDR documents are explicitly described in Annex XIII: the performance evaluation plan (PEP) and the performance evaluation report (PER).

EU issues guidance on surveillance of IVDs on the market with certificates under the Directives The In Vitro Diagnostic Medical Devices Regulation (IVDR) (EU 2017/746) permits devices covered by valid certificates issued by a Notified Body under the IVD Directive (98/79/EC) to be placed on the market or put into service after the date of application of the IVDR, and no later than 26 May 2025, under certain conditions. This is covered by the transitional provisions in Article 110(2) and 110(3) of the IVDR. The guidance describes such devices with the term ‘legacy devices’.

The FDA launched a pilot programme for electronic premarket submissions to demonstrate that the device to be marketed is substantially equivalent to a legally marketed device, known as 510(k) submissions. This was known as the eSubmitter electronic submission template. This pilot programme ended in May 2021.

Analytical performance is not a new concept for IVDs, having been described in the IVDD since 1998. Many of the same analytical performance characteristics are present in both IVDD and IVDR, but IVDR seeks to expand on what nature of data should be provided. Section 9.1 of Annex I describes the analytical performance requirements, but as all scenarios of device type and intended purpose cannot be anticipated, the onus is on the manufacturer to provide a rationale for any characteristics that are not applicable to their device.

The US FDA has issued draft guidance, in the form of a Question and Answers document, on conducting remote regulatory assessment (RRA). The draft guidance is intended to provide transparency and greater consistency. The guidance notes that practices adopted during the pandemic for remote interactions have proven useful in reducing delays in approval or authorization of marketing submissions. They have also been valuable in:

For those with long memories, the ’Blue Guide’ represents the descriptor for the UK Department of Health ‘Guide to Good Manufacturing Practice (GMP) for sterile medical devices’. This was first published in 1979 and updated in 1981 and 1990. This ‘Blue Guide’ was one of a series of rainbow-coloured GMP documents for specific types of medical devices that were replaced first by the BS EN 46000 series of standards and supporting guidance documents, where EN 46001 was Quality systems - Medical devices - Particular requirements for the application of EN ISO 9001, and ultimately EN ISO 13485 - Medical devices — Quality management systems — Requirements for regulatory purposes.

Performance evaluation is defined in Article 2 of IVDR as ‘an assessment and analysis of data to establish or verify the scientific validity, the analytical and, where applicable, the clinical performance of a device’.

US Government Agencies are directed by the US Federal Government to use voluntary consensus standards rather than developing their own, unique standards, unless voluntary consensus standards are inconsistent with law or otherwise impractical.

The transitional arrangements for the Regulations allow for medical devices and in vitro diagnostic medical devices with valid certificates or declarations of conformity to the Directives to continue to be placed on the market for finite periods.

The European Commission has published the second amendments to the lists of harmonised standards in the Official Journal of the European Communities (OJ). Harmonised standards listed in the OJ provide a presumption of conformity with the with relevant requirements of the Medical Devices Regulation (MDR) and In Vitro Diagnostic Medical Devices Regulation (IVDR) covered by those standards or applicable parts of standards...

The Medical Device Coordination Group (MDCG) is composed of representatives of Member States and chaired by the EU Commission. The MDCG has endorsed a guidance note on the borderline between medical devices and medicinal products.

Standards are used to support the regulatory process because they are developed in accordance with set principles of transparency, openness to participation by interested stakeholders, balance of representation and due process. The way that standards are developed is intended to assure that, while many interests are considered, no single party wields disproportionate influence.

The requirements for medical devices in the EU, in both the MDD and Regulations, refer in a number of places to the need to ‘take into account the generally acknowledged state of the art’ in relation to safety and performance of medical devices.

The EU Medical Devices Regulation (MDR), EU 2017/745, and In Vitro Diagnostic Medical Devices Regulation (IVDR), EU 2017/746, were not implemented in Great Britain, i.e., England, Scotland and Wales. Northern Ireland has a special status as EU rules will continue to apply there.

The US Food and Drug Administration (FDA) has published its proposed rule to align the US medical device quality system regulation, 21 CFR Part 820, with ISO 13485 – Medical devices – Quality Management Systems – Requirements for regulatory purposes.

It is important to be aware that the MDR and IVDR will not be implemented in England, Scotland and Wales. In this context, the distinction between Great Britain (GB) – England, Scotland and Wales – and the United Kingdom, which comprises Great Britain and Northern Ireland, is relevant. Northern Ireland will have a special status as EU rules will continue to apply there. The Northern Ireland Protocol is a key part of the agreement on the UK withdrawal from the European Union. The effect of the Northern Ireland Protocol is that products on the Northern Ireland market, including medical devices, are required to comply with EU Regulations and Directives as well as with UK law. Separate requirements regarding CE marking will apply in Northern Ireland.

It can be anticipated that most manufacturers will demonstrate compliance with the MDR by means of conformity assessment based on a QMS and assessment of technical documentation, as specified in MDR Annex IX. Section 2.2(c) requires that the documentation to be submitted for the assessment of the QMS includes an adequate description of: the procedures and techniques for monitoring, verifying, validating and controlling the design of the devices and the corresponding documentation as well as the data and records arising from those procedures and techniques. Eight different elements that the procedures and techniques need to address are specified and, in brief, are...

MDR Article 74, Clinical investigations regarding devices bearing the CE marking, refers to a PMCF investigation as a clinical investigation conducted to further assess, within the scope of its intended purpose, a device which already bears the CE marking...

A European amendment to EN ISO 14971 - Medical devices - Application of risk management to medical devices was published in December 2021. The amendment is designated EN ISO 14971:2019+A11:2021. The amendment replaces the European Foreword and adds two new Annex Zs...

The In Vitro Diagnostic Medical Devices Regulation (IVDR) was adopted in 2017. The date of application of the IVDR was originally scheduled as 26 May 2022.

BS EN ISO 15223-1:2021 includes additional symbols to support European regulatory requirements.

Medical Device Single Audit Program (MDSAP) Audit Guide updated with revised requirements from Japan.

The definition of the intended purpose and indications for use of the device is a critical first step which shapes all subsequent aspects of the evaluation.

The purpose of the clinical evaluation is to demonstrate, with objective and scientifically valid evidence, that the device does what it is supposed to do, achieves its intended clinical benefits (whether direct or indirect) and that the benefit-risk conclusion is acceptable in comparison to other available therapeutic or diagnostic options.

There has been significant evolution in the European regulatory landscape over the past 10–15 years, particularly with respect to requirements for clinical evaluation.

The Medicines and Healthcare products Regulatory Agency (MHRA) are looking at ways to update the UK regulations on placing medical devices on the UK market.

An amendment to EN ISO 13485:2016 – Medical devices – Quality management systems – Requirements for regulatory purposes – was published in September 2021.

Under the EU MDR, there are several new provisions to increase transparency and access to information. The foundation for these instruments is encapsulated in the recitals. With respect to the Summary of Safety and Clinical Performance (SSCP), Recital 43 is particularly relevant.

Depending on device transition timing to the Regulations, manufacturers may need to submit UDI and Device Registration information for legacy devices in EUDAMED.

EUDAMED functionality is intended to provide for the exchange of information regarding vigilance reporting, clinical investigations, certificate notifications and registration of devices and economic operators, as well as exchange of information between competent authorities.

The new EU MDR 2017/745 and IVDR 2017/746 regulations require the assignment of a Basic UDI-DI to medical devices. The concept of a Basic UDI-DI is new and currently unique to the EU. The purpose and use of the Basic UDI-DI is different from the use of the device UDI-DI.

The European Commission has published lists of the first standards to be harmonized under the Medical Device Regulation - 2017/745, (MDR) - and In Vitro Diagnostic Medical Devices Regulation – 2017/746 (IVDR).

The Unique Device Identification (UDI) System is specified in Article 27 of the Medical Devices Regulation - (EU) 2017/745 - (MDR) and Article 24 of the In Vitro Diagnostic Medical Devices Regulation - (EU) 2017/746 - (IVDR).

A Standardization Request from the European Commission to the European Standards Organisations , CEN and CENELEC, provides the legal basis for harmonising standards. Agreement of this request allows publication of references to harmonised standards that provide a presumption of conformity under the MDR and IVDR to start.

Three Commission Implementing Decisions for harmonised standards were adopted in April 2021 and published in the Official Journal. There is a separate decision for each of the three directives. These implementing decisions present the final updates to the list of harmonised standards that give a presumption of conformity for the directives for medical devices.

BS AAMI 34971 Guidance on the Application of ISO 14971 to Artificial Intelligence and Machine Learning is a guidance document for applying a risk management process when evaluating medical technologies that utilise artificial intelligence (AI) and machine learning (ML). This guidance document will address the same types of risk that are already covered in ISO 14971, but it focusses on those risks that are elevated or unique to AI-based medical devices.

From a regulatory perspective, the intermixing of device technologies and pharmaceutical innovation associated with combination products requires greater coordination and communication between the various stakeholders.

The Medical Device Coordination Group (MDCG) is composed of representatives of Member States and chaired by the EU Commission. The MDCG has issued a guidance document on standardization for medical devices. As with all the MDCG guidance, it cannot be regarded as reflecting the official position of the European Commission, or as being legally binding.

The manufacturer has responsibility for the legal compliance of products intended to be placed on the market. Within this responsibility, the manufacturer has the choice of whether or not to use a particular standard. The manufacturer also needs to be able to demonstrate how they have “taken into account” the state of the art. Given that there have been a number of statements that the most recent published editions of standards should be considered as reflecting state-of-the-art, this suggests that manufacturers should give consideration to the latest version of a relevant standard, even if it is not harmonized.

As per the Regulations Article15(1) and as interpreted by the MDCG Guidance 2019-7, manufacturers are required to have available within their organisation at least one PRRC with proper expertise in the field of medical devices or in vitro medical devices, as applicable, in the European Union. This is valid for enterprises which employ at least 50 persons and whose annual turnover and/or annual balance sheet total exceeds EUR 10 million.

With the Medical Device Regulation – MDR (EU 2017/745) and In Vitro Diagnostic Regulation – IVDR (EU 2017/746), European regulators aim to ensure companies have a regulatory expert – a Person Responsible for Regulatory Compliance (PRRC) – at their disposal, to ensure that the company is meeting certain specific EU requirements.

An effective sterile barrier system is essential to maintain the sterility of terminally sterilized medical devices. BS EN ISO 11607-1 - Packaging for terminally sterilized medical devices — Part 1: Requirements for materials, sterile barrier systems and packaging systems - specifies requirements for materials and pre-formed systems intended for use in packaging systems for terminally sterilized medical devices. BS EN ISO 11607-2 - Packaging for terminally sterilized medical devices — Part 2: Validation requirements for forming, sealing and assembly processes - describes the validation requirements for forming, sealing and assembly processes.

Following the end of the Brexit transition period, the EU Medical Devices Regulation (MDR) and In Vitro Diagnostic Medical Devices Regulation (IVDR) will not be implemented in England, Scotland and Wales. The UK Medical Devices Regulations 2002 (SI 2002 No 618, as amended) continue to have effect. The UK Conformity Assessment (UKCA) mark will apply to medical devices, including in vitro diagnostic medical devices. Northern Ireland will have a special status as EU rules will continue to apply there.

Following the end of the Brexit transition period, the EU Medical Devices Regulation (MDR) and In Vitro Diagnostic Medical Devices Regulation (IVDR) will not be transposed into law in Great Britain. In this context, it is important to be aware of the distinction between Great Britain – England, Scotland and Wales – and the United Kingdom, which comprises Great Britain and Northern Ireland. The MDR and IVDR will not be implemented in England, Scotland and Wales. Northern Ireland will have a special status as EU rules will continue to apply there.

The Compliance and Enforcement Group (COEN) provides exchange of information between Competent Authorities (CA) responsible for market surveillance (MS) of medical devices (MD) and coordinates their enforcement activities. COEN created a working group to address nonconformities under the Medical Devices Directive related to the instructions for use (IFU) for resterilizable devices.

The Medical Device Single Audit Program - MDSAP - was developed by the International Medical Device Regulators Forum (IMDRF) to conduct regulatory audits of quality management systems (QMS) of manufacturers of medical devices.

EN ISO 11135 - Sterilization of health-care products — Ethylene oxide — Requirements for the development, validation and routine control of a sterilization process for medical devices – specifies requirements, and provides guidance, for development, validation and routine control of ethylene oxide (EO) sterilization processes. EN ISO 11135 was published in 2014 and an amendment to the standard was adopted in 2019.

The FDA has defined stand-alone medical software in the Preamble Section AA Special Requirements for Stand-Alone Software—Final § 801.50 of the Unique Device Identification (UDI) System Regulations as ‘medical software that is itself a medical device and is not a component, part, or accessory of a medical device’.

The IVDR (EU 2017/746) brings new requirements for manufacturers with regard to Performance Evaluation and Clinical Performance Studies and one of those is the need for a Performance Evaluation Plan (PEP) and Performance Evaluation Report (PER).

A new technical specification has been issued as Part 4 to the ISO 11137 series of standards for radiation sterilization using gamma, electron beam or x-ray irradiation.

The IMDRF defines ‘SaMD’ as ‘software intended to be used for one or more medical purposes that perform these purposes without being part of a hardware medical device’.

Medical Device Coordination Group (MDCG) endorses guidance for notified bodies.